Matthew Daley
Concepts (493)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccination | 111 | 2026 | 1423 | 10.120 |
Why?
| | Vaccines | 41 | 2025 | 389 | 7.650 |
Why?
| | Vaccination Coverage | 22 | 2026 | 103 | 6.460 |
Why?
| | Influenza Vaccines | 44 | 2025 | 529 | 5.340 |
Why?
| | Immunization Schedule | 34 | 2025 | 187 | 4.430 |
Why?
| | Influenza, Human | 31 | 2025 | 617 | 3.810 |
Why?
| | Immunization Programs | 20 | 2024 | 194 | 3.010 |
Why?
| | Papillomavirus Vaccines | 15 | 2022 | 297 | 2.510 |
Why?
| | Immunization | 23 | 2024 | 374 | 2.410 |
Why?
| | Advisory Committees | 20 | 2024 | 230 | 2.210 |
Why?
| | Papillomavirus Infections | 10 | 2022 | 345 | 2.180 |
Why?
| | Electronic Health Records | 29 | 2025 | 1177 | 2.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 18 | 2025 | 1416 | 2.060 |
Why?
| | Child, Preschool | 86 | 2026 | 11799 | 2.000 |
Why?
| | Adverse Drug Reaction Reporting Systems | 14 | 2022 | 81 | 1.990 |
Why?
| | Infant | 85 | 2026 | 10039 | 1.860 |
Why?
| | United States | 99 | 2026 | 15988 | 1.660 |
Why?
| | Practice Patterns, Physicians' | 18 | 2024 | 1358 | 1.610 |
Why?
| | Eczema | 3 | 2022 | 66 | 1.570 |
Why?
| | Hypertension | 10 | 2026 | 1264 | 1.560 |
Why?
| | School Health Services | 11 | 2018 | 224 | 1.520 |
Why?
| | Child | 105 | 2026 | 22657 | 1.520 |
Why?
| | Humans | 247 | 2026 | 144957 | 1.510 |
Why?
| | Patient Acceptance of Health Care | 13 | 2022 | 886 | 1.450 |
Why?
| | Social Media | 4 | 2021 | 171 | 1.440 |
Why?
| | Pediatric Obesity | 8 | 2025 | 638 | 1.430 |
Why?
| | Parents | 16 | 2023 | 1403 | 1.430 |
Why?
| | Body Mass Index | 15 | 2026 | 2438 | 1.400 |
Why?
| | Adolescent | 95 | 2026 | 22453 | 1.400 |
Why?
| | Reminder Systems | 7 | 2016 | 141 | 1.400 |
Why?
| | Female | 166 | 2026 | 78376 | 1.390 |
Why?
| | Pregnancy Complications, Infectious | 7 | 2025 | 428 | 1.240 |
Why?
| | Male | 141 | 2026 | 72406 | 1.230 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 10 | 2022 | 257 | 1.150 |
Why?
| | Internet | 6 | 2024 | 700 | 1.150 |
Why?
| | Rural Population | 5 | 2025 | 650 | 1.140 |
Why?
| | Urban Population | 3 | 2025 | 491 | 1.130 |
Why?
| | Pneumococcal Vaccines | 10 | 2025 | 130 | 1.090 |
Why?
| | Antihypertensive Agents | 4 | 2026 | 511 | 1.080 |
Why?
| | Colorado | 35 | 2026 | 4564 | 1.070 |
Why?
| | Information Dissemination | 2 | 2020 | 223 | 0.990 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1915 | 0.980 |
Why?
| | Libraries, Medical | 2 | 2024 | 11 | 0.970 |
Why?
| | Practice Guidelines as Topic | 15 | 2024 | 1563 | 0.950 |
Why?
| | Adult | 89 | 2026 | 40506 | 0.930 |
Why?
| | Young Adult | 58 | 2026 | 14126 | 0.930 |
Why?
| | Pediatrics | 17 | 2020 | 1115 | 0.910 |
Why?
| | Measles | 3 | 2022 | 46 | 0.900 |
Why?
| | Pandemics | 9 | 2025 | 1695 | 0.890 |
Why?
| | Product Surveillance, Postmarketing | 6 | 2017 | 73 | 0.880 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 10 | 2025 | 91 | 0.870 |
Why?
| | Transportation | 1 | 2025 | 54 | 0.860 |
Why?
| | Retrospective Studies | 44 | 2026 | 17101 | 0.850 |
Why?
| | Asthma | 5 | 2022 | 1768 | 0.840 |
Why?
| | Thrombocytopenia | 3 | 2022 | 205 | 0.790 |
Why?
| | Data Collection | 16 | 2017 | 635 | 0.790 |
Why?
| | Ambulatory Care | 5 | 2024 | 603 | 0.770 |
Why?
| | Weight Gain | 6 | 2026 | 559 | 0.760 |
Why?
| | Egg Hypersensitivity | 1 | 2022 | 28 | 0.750 |
Why?
| | Guideline Adherence | 8 | 2024 | 589 | 0.740 |
Why?
| | Hepatitis B Vaccines | 4 | 2026 | 43 | 0.740 |
Why?
| | Rotavirus Vaccines | 7 | 2025 | 37 | 0.730 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 174 | 0.720 |
Why?
| | Abortion, Spontaneous | 4 | 2025 | 115 | 0.710 |
Why?
| | Attitude of Health Personnel | 13 | 2020 | 1186 | 0.700 |
Why?
| | Pregnancy | 25 | 2026 | 7191 | 0.700 |
Why?
| | Data Mining | 3 | 2022 | 117 | 0.680 |
Why?
| | Blood Pressure | 5 | 2024 | 1769 | 0.670 |
Why?
| | Surveys and Questionnaires | 17 | 2025 | 6053 | 0.670 |
Why?
| | Whooping Cough | 6 | 2023 | 55 | 0.660 |
Why?
| | Peanut Hypersensitivity | 1 | 2022 | 143 | 0.660 |
Why?
| | Vaccination Refusal | 2 | 2018 | 64 | 0.650 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2018 | 28 | 0.650 |
Why?
| | Anaphylaxis | 3 | 2019 | 102 | 0.650 |
Why?
| | Seasons | 11 | 2025 | 556 | 0.640 |
Why?
| | Obesity | 7 | 2022 | 3082 | 0.640 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2020 | 16 | 0.630 |
Why?
| | Reimbursement Mechanisms | 3 | 2018 | 80 | 0.620 |
Why?
| | Education, Medical, Continuing | 1 | 2021 | 132 | 0.620 |
Why?
| | Geographic Information Systems | 1 | 2020 | 46 | 0.620 |
Why?
| | Weight Loss | 6 | 2025 | 837 | 0.610 |
Why?
| | Syncope | 2 | 2017 | 55 | 0.610 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 428 | 0.600 |
Why?
| | Family Practice | 8 | 2015 | 404 | 0.600 |
Why?
| | Pneumococcal Infections | 3 | 2025 | 103 | 0.590 |
Why?
| | Mothers | 3 | 2025 | 775 | 0.580 |
Why?
| | Information Storage and Retrieval | 2 | 2020 | 121 | 0.580 |
Why?
| | Haemophilus Vaccines | 4 | 2025 | 29 | 0.560 |
Why?
| | Vaccines, Attenuated | 7 | 2023 | 129 | 0.560 |
Why?
| | Pneumonia | 1 | 2024 | 631 | 0.550 |
Why?
| | Middle Aged | 59 | 2026 | 35928 | 0.550 |
Why?
| | Infant, Newborn | 19 | 2026 | 6434 | 0.550 |
Why?
| | Population Surveillance | 7 | 2020 | 485 | 0.540 |
Why?
| | Hepatitis B | 3 | 2026 | 66 | 0.540 |
Why?
| | Delivery of Health Care | 5 | 2019 | 947 | 0.540 |
Why?
| | Montana | 3 | 2023 | 19 | 0.540 |
Why?
| | Cohort Studies | 28 | 2025 | 5965 | 0.530 |
Why?
| | Urinary Tract Infections | 1 | 2020 | 203 | 0.530 |
Why?
| | Incidence | 17 | 2021 | 2883 | 0.520 |
Why?
| | Drug Hypersensitivity | 2 | 2019 | 90 | 0.520 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 5872 | 0.510 |
Why?
| | Poliovirus Vaccine, Inactivated | 2 | 2014 | 27 | 0.510 |
Why?
| | Learning | 1 | 2021 | 452 | 0.490 |
Why?
| | Healthcare Disparities | 1 | 2023 | 728 | 0.490 |
Why?
| | Prehypertension | 2 | 2013 | 27 | 0.490 |
Why?
| | Self Report | 4 | 2025 | 873 | 0.490 |
Why?
| | Databases, Pharmaceutical | 1 | 2016 | 5 | 0.480 |
Why?
| | Aluminum | 3 | 2022 | 43 | 0.470 |
Why?
| | Primary Health Care | 11 | 2024 | 1734 | 0.470 |
Why?
| | Treatment Refusal | 3 | 2013 | 98 | 0.470 |
Why?
| | Disease Outbreaks | 3 | 2011 | 422 | 0.470 |
Why?
| | Computers, Handheld | 1 | 2016 | 26 | 0.460 |
Why?
| | Professional-Family Relations | 2 | 2015 | 153 | 0.460 |
Why?
| | Quality Assurance, Health Care | 3 | 2014 | 340 | 0.440 |
Why?
| | Databases, Factual | 9 | 2025 | 1486 | 0.440 |
Why?
| | Age Factors | 12 | 2025 | 3335 | 0.440 |
Why?
| | Consumer Health Information | 1 | 2015 | 49 | 0.440 |
Why?
| | Bias | 7 | 2021 | 202 | 0.430 |
Why?
| | Risk Assessment | 15 | 2022 | 3676 | 0.430 |
Why?
| | Safety | 5 | 2018 | 356 | 0.420 |
Why?
| | Prevalence | 10 | 2025 | 2836 | 0.420 |
Why?
| | Hepatitis A Vaccines | 3 | 2026 | 20 | 0.410 |
Why?
| | Deductibles and Coinsurance | 1 | 2014 | 12 | 0.410 |
Why?
| | Overweight | 5 | 2020 | 609 | 0.410 |
Why?
| | Hepatitis A | 2 | 2026 | 25 | 0.390 |
Why?
| | Dental Hygienists | 1 | 2013 | 14 | 0.390 |
Why?
| | Decision Making | 3 | 2018 | 980 | 0.380 |
Why?
| | Health Care Surveys | 8 | 2013 | 539 | 0.370 |
Why?
| | Drug Approval | 6 | 2021 | 91 | 0.370 |
Why?
| | Chronic Disease | 5 | 2022 | 1813 | 0.370 |
Why?
| | Central Nervous System Stimulants | 1 | 2014 | 185 | 0.360 |
Why?
| | Interrupted Time Series Analysis | 2 | 2024 | 75 | 0.360 |
Why?
| | Measles-Mumps-Rubella Vaccine | 5 | 2022 | 47 | 0.350 |
Why?
| | Patient Compliance | 1 | 2016 | 589 | 0.350 |
Why?
| | Trust | 1 | 2013 | 153 | 0.350 |
Why?
| | Vaccines, Inactivated | 6 | 2020 | 70 | 0.350 |
Why?
| | Attitude to Health | 4 | 2018 | 436 | 0.340 |
Why?
| | Immunization, Secondary | 6 | 2025 | 91 | 0.340 |
Why?
| | Myocarditis | 2 | 2022 | 102 | 0.330 |
Why?
| | Community Health Services | 1 | 2013 | 234 | 0.330 |
Why?
| | Aged | 28 | 2026 | 25947 | 0.330 |
Why?
| | Licensure, Medical | 1 | 2010 | 18 | 0.320 |
Why?
| | Premature Birth | 3 | 2024 | 380 | 0.320 |
Why?
| | Risk Factors | 15 | 2025 | 10792 | 0.310 |
Why?
| | Herpes Zoster Vaccine | 4 | 2023 | 154 | 0.310 |
Why?
| | Vaccines, Synthetic | 4 | 2026 | 138 | 0.310 |
Why?
| | Multivariate Analysis | 5 | 2013 | 1540 | 0.310 |
Why?
| | Patient-Centered Care | 2 | 2013 | 544 | 0.300 |
Why?
| | Insurance, Health | 4 | 2018 | 303 | 0.300 |
Why?
| | Haemophilus Infections | 2 | 2025 | 45 | 0.300 |
Why?
| | Lisinopril | 2 | 2026 | 15 | 0.300 |
Why?
| | Phentermine | 2 | 2019 | 14 | 0.300 |
Why?
| | Infant Behavior | 1 | 2008 | 26 | 0.290 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 3 | 2018 | 13 | 0.280 |
Why?
| | Anti-Obesity Agents | 2 | 2019 | 66 | 0.280 |
Why?
| | Pregnancy Outcome | 4 | 2025 | 476 | 0.280 |
Why?
| | Proportional Hazards Models | 7 | 2021 | 1325 | 0.270 |
Why?
| | Natural Language Processing | 2 | 2019 | 103 | 0.270 |
Why?
| | Insurance, Health, Reimbursement | 3 | 2014 | 97 | 0.270 |
Why?
| | Mass Screening | 2 | 2014 | 1348 | 0.270 |
Why?
| | Hospitalization | 7 | 2026 | 2434 | 0.270 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 914 | 0.270 |
Why?
| | Risk | 6 | 2022 | 911 | 0.270 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 923 | 0.260 |
Why?
| | Rotavirus Infections | 3 | 2021 | 35 | 0.260 |
Why?
| | Logistic Models | 7 | 2019 | 2119 | 0.260 |
Why?
| | Firearms | 2 | 2024 | 435 | 0.250 |
Why?
| | Vaccines, Combined | 4 | 2023 | 49 | 0.250 |
Why?
| | Atenolol | 1 | 2026 | 7 | 0.240 |
Why?
| | Clonidine | 1 | 2026 | 33 | 0.240 |
Why?
| | Propranolol | 1 | 2026 | 44 | 0.240 |
Why?
| | Quetiapine Fumarate | 1 | 2026 | 26 | 0.240 |
Why?
| | Aripiprazole | 1 | 2026 | 20 | 0.240 |
Why?
| | Risperidone | 1 | 2026 | 29 | 0.240 |
Why?
| | Spironolactone | 1 | 2026 | 39 | 0.240 |
Why?
| | Stillbirth | 2 | 2024 | 77 | 0.230 |
Why?
| | Parent-Child Relations | 1 | 2008 | 270 | 0.230 |
Why?
| | Haemophilus influenzae type b | 1 | 2025 | 12 | 0.230 |
Why?
| | Meningococcal Vaccines | 4 | 2022 | 58 | 0.220 |
Why?
| | Attention | 1 | 2008 | 458 | 0.220 |
Why?
| | Cluster Analysis | 2 | 2023 | 521 | 0.220 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2025 | 39 | 0.220 |
Why?
| | Poisson Distribution | 5 | 2018 | 78 | 0.220 |
Why?
| | Case-Control Studies | 12 | 2025 | 3608 | 0.220 |
Why?
| | Travel | 2 | 2023 | 136 | 0.220 |
Why?
| | Fathers | 1 | 2025 | 51 | 0.220 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 412 | 0.210 |
Why?
| | Guillain-Barre Syndrome | 3 | 2014 | 22 | 0.210 |
Why?
| | Infant, Small for Gestational Age | 2 | 2024 | 109 | 0.210 |
Why?
| | Physicians, Family | 3 | 2011 | 173 | 0.210 |
Why?
| | Registries | 5 | 2011 | 2385 | 0.210 |
Why?
| | Pregnancy Trimester, First | 1 | 2024 | 136 | 0.200 |
Why?
| | Models, Theoretical | 2 | 2020 | 582 | 0.200 |
Why?
| | Antipsychotic Agents | 1 | 2026 | 214 | 0.200 |
Why?
| | Health Policy | 2 | 2023 | 401 | 0.200 |
Why?
| | International Classification of Diseases | 2 | 2020 | 147 | 0.200 |
Why?
| | Epidural Neoplasms | 1 | 2003 | 1 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2025 | 136 | 0.200 |
Why?
| | Herpes Zoster | 2 | 2023 | 315 | 0.200 |
Why?
| | Seizures | 3 | 2018 | 477 | 0.200 |
Why?
| | Gastrointestinal Diseases | 3 | 2018 | 216 | 0.200 |
Why?
| | Tetanus | 1 | 2023 | 26 | 0.200 |
Why?
| | Prospective Studies | 9 | 2023 | 7997 | 0.200 |
Why?
| | Regression Analysis | 3 | 2014 | 1003 | 0.190 |
Why?
| | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 5 | 0.190 |
Why?
| | Depression, Postpartum | 1 | 2025 | 128 | 0.190 |
Why?
| | Anticonvulsants | 1 | 2025 | 242 | 0.190 |
Why?
| | Library Surveys | 1 | 2022 | 1 | 0.190 |
Why?
| | Cholera Vaccines | 1 | 2022 | 1 | 0.190 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 2022 | 5 | 0.190 |
Why?
| | Time Factors | 13 | 2022 | 7183 | 0.190 |
Why?
| | Burkitt Lymphoma | 1 | 2003 | 62 | 0.190 |
Why?
| | Cholera | 1 | 2022 | 9 | 0.190 |
Why?
| | Checklist | 1 | 2024 | 108 | 0.190 |
Why?
| | Chorioamnionitis | 1 | 2023 | 45 | 0.190 |
Why?
| | Cultural Diversity | 1 | 2024 | 87 | 0.190 |
Why?
| | Sentinel Surveillance | 2 | 2016 | 46 | 0.180 |
Why?
| | Chickenpox Vaccine | 4 | 2022 | 75 | 0.180 |
Why?
| | Urticaria | 1 | 2022 | 38 | 0.180 |
Why?
| | Neoplasms | 1 | 2018 | 2884 | 0.180 |
Why?
| | Health Planning Guidelines | 1 | 2022 | 24 | 0.180 |
Why?
| | Antidepressive Agents | 1 | 2024 | 248 | 0.180 |
Why?
| | Internal Medicine | 3 | 2010 | 280 | 0.180 |
Why?
| | Seizures, Febrile | 1 | 2022 | 23 | 0.180 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2013 | 157 | 0.180 |
Why?
| | Exanthema | 1 | 2022 | 84 | 0.180 |
Why?
| | Antimicrobial Stewardship | 1 | 2024 | 130 | 0.180 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 91 | 0.180 |
Why?
| | Drug Prescriptions | 1 | 2024 | 285 | 0.180 |
Why?
| | Minnesota | 3 | 2017 | 169 | 0.170 |
Why?
| | Arachis | 1 | 2022 | 108 | 0.170 |
Why?
| | Rotavirus | 1 | 2021 | 20 | 0.170 |
Why?
| | Pharmacoepidemiology | 1 | 2021 | 22 | 0.170 |
Why?
| | United States Food and Drug Administration | 4 | 2024 | 205 | 0.170 |
Why?
| | Wounds, Gunshot | 1 | 2024 | 258 | 0.170 |
Why?
| | Epilepsy | 1 | 2025 | 387 | 0.160 |
Why?
| | Body Height | 1 | 2022 | 202 | 0.160 |
Why?
| | Papillomaviridae | 2 | 2018 | 115 | 0.160 |
Why?
| | Language | 1 | 2024 | 323 | 0.160 |
Why?
| | Outpatients | 1 | 2024 | 443 | 0.160 |
Why?
| | Managed Care Programs | 4 | 2015 | 140 | 0.160 |
Why?
| | Bursitis | 1 | 2020 | 9 | 0.160 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2014 | 269 | 0.160 |
Why?
| | Pyelonephritis | 1 | 2020 | 11 | 0.160 |
Why?
| | Models, Statistical | 4 | 2023 | 682 | 0.160 |
Why?
| | Antigens | 2 | 2021 | 347 | 0.160 |
Why?
| | Cystitis | 1 | 2020 | 23 | 0.160 |
Why?
| | Cephalexin | 1 | 2020 | 14 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2022 | 255 | 0.150 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 42 | 0.150 |
Why?
| | Hepatitis A Virus, Human | 1 | 2019 | 2 | 0.150 |
Why?
| | Vaccine Potency | 1 | 2019 | 6 | 0.150 |
Why?
| | Appetite Depressants | 1 | 2019 | 19 | 0.150 |
Why?
| | Medical Record Linkage | 1 | 2020 | 68 | 0.150 |
Why?
| | Epidemiological Monitoring | 1 | 2019 | 69 | 0.150 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 321 | 0.150 |
Why?
| | Public Health | 2 | 2022 | 566 | 0.150 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1327 | 0.150 |
Why?
| | California | 2 | 2019 | 475 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 988 | 0.140 |
Why?
| | Intention | 1 | 2020 | 183 | 0.140 |
Why?
| | Sunburn | 1 | 2018 | 26 | 0.140 |
Why?
| | Environment | 1 | 2020 | 305 | 0.140 |
Why?
| | Nevus | 1 | 2018 | 26 | 0.140 |
Why?
| | Respiratory Tract Infections | 3 | 2026 | 398 | 0.140 |
Why?
| | Patient Participation | 2 | 2012 | 433 | 0.140 |
Why?
| | Condylomata Acuminata | 1 | 2018 | 7 | 0.140 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2018 | 40 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2925 | 0.140 |
Why?
| | Delivery of Health Care, Integrated | 3 | 2021 | 299 | 0.140 |
Why?
| | New Zealand | 1 | 2018 | 54 | 0.140 |
Why?
| | Physicians | 4 | 2012 | 940 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2947 | 0.130 |
Why?
| | Shoulder Joint | 1 | 2020 | 198 | 0.130 |
Why?
| | Biometry | 1 | 2018 | 68 | 0.130 |
Why?
| | Odds Ratio | 6 | 2019 | 1077 | 0.130 |
Why?
| | Rhinitis, Allergic | 1 | 2018 | 42 | 0.130 |
Why?
| | Communicable Diseases | 1 | 2020 | 163 | 0.130 |
Why?
| | Aged, 80 and over | 9 | 2025 | 8279 | 0.130 |
Why?
| | Blood Pressure Determination | 2 | 2015 | 144 | 0.130 |
Why?
| | Parental Consent | 2 | 2014 | 25 | 0.130 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 68 | 0.130 |
Why?
| | Siblings | 1 | 2018 | 195 | 0.130 |
Why?
| | Sex Factors | 3 | 2021 | 2114 | 0.130 |
Why?
| | Family Health | 1 | 2018 | 191 | 0.130 |
Why?
| | Infant, Premature | 1 | 2022 | 611 | 0.130 |
Why?
| | Thrombosis | 1 | 2021 | 393 | 0.130 |
Why?
| | Cost-Benefit Analysis | 3 | 2015 | 636 | 0.130 |
Why?
| | Australia | 1 | 2018 | 286 | 0.130 |
Why?
| | Health Maintenance Organizations | 2 | 2014 | 105 | 0.130 |
Why?
| | Body Weight | 2 | 2018 | 978 | 0.130 |
Why?
| | Vaccines, Conjugate | 3 | 2022 | 60 | 0.130 |
Why?
| | United Kingdom | 1 | 2018 | 338 | 0.130 |
Why?
| | Diastole | 1 | 2017 | 143 | 0.120 |
Why?
| | Systole | 1 | 2017 | 178 | 0.120 |
Why?
| | Diagnostic Errors | 1 | 2018 | 175 | 0.120 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 365 | 0.120 |
Why?
| | Health Services Research | 3 | 2022 | 396 | 0.120 |
Why?
| | Maternal Exposure | 1 | 2018 | 213 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2019 | 321 | 0.120 |
Why?
| | Follow-Up Studies | 6 | 2025 | 5417 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1389 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 388 | 0.120 |
Why?
| | Food Hypersensitivity | 1 | 2018 | 164 | 0.120 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 2171 | 0.120 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2017 | 193 | 0.120 |
Why?
| | Data Accuracy | 1 | 2016 | 65 | 0.110 |
Why?
| | Quality Improvement | 1 | 2024 | 1291 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3415 | 0.110 |
Why?
| | Public Health Surveillance | 3 | 2020 | 83 | 0.110 |
Why?
| | Depression | 1 | 2025 | 1559 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Pilot Projects | 2 | 2022 | 1890 | 0.110 |
Why?
| | Contraceptives, Oral | 1 | 2014 | 37 | 0.110 |
Why?
| | Social Welfare | 1 | 2014 | 27 | 0.110 |
Why?
| | Needs Assessment | 1 | 2017 | 404 | 0.110 |
Why?
| | Direct Service Costs | 1 | 2014 | 8 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 949 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2015 | 245 | 0.100 |
Why?
| | Breast Feeding | 1 | 2018 | 448 | 0.100 |
Why?
| | Focus Groups | 2 | 2014 | 573 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2021 | 3890 | 0.100 |
Why?
| | Bacterial Capsules | 2 | 2025 | 33 | 0.100 |
Why?
| | Costs and Cost Analysis | 1 | 2014 | 220 | 0.100 |
Why?
| | Research Design | 4 | 2022 | 1137 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2014 | 182 | 0.090 |
Why?
| | Health Promotion | 1 | 2019 | 774 | 0.090 |
Why?
| | Maternal Age | 2 | 2023 | 126 | 0.090 |
Why?
| | Health Services | 1 | 2013 | 115 | 0.090 |
Why?
| | Computer Simulation | 2 | 2013 | 1026 | 0.090 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 17 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2019 | 675 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 732 | 0.090 |
Why?
| | Mass Vaccination | 1 | 2011 | 18 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 324 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2018 | 847 | 0.080 |
Why?
| | Prescriptions | 2 | 2022 | 76 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2025 | 2584 | 0.080 |
Why?
| | Environmental Exposure | 1 | 2015 | 590 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2023 | 2832 | 0.080 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1098 | 0.080 |
Why?
| | Physicians, Primary Care | 1 | 2013 | 207 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 427 | 0.080 |
Why?
| | Drug Recalls | 1 | 2010 | 3 | 0.080 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2010 | 47 | 0.080 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2023 | 81 | 0.080 |
Why?
| | Medical Records Systems, Computerized | 1 | 2011 | 95 | 0.080 |
Why?
| | Medicare Part D | 1 | 2010 | 23 | 0.080 |
Why?
| | Polysaccharides, Bacterial | 1 | 2010 | 67 | 0.080 |
Why?
| | Haemophilus influenzae | 1 | 2010 | 67 | 0.080 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2010 | 61 | 0.080 |
Why?
| | Pertussis Vaccine | 1 | 2009 | 24 | 0.070 |
Why?
| | Chickenpox | 1 | 2010 | 81 | 0.070 |
Why?
| | Patient Education as Topic | 2 | 2011 | 780 | 0.070 |
Why?
| | Videotape Recording | 1 | 2008 | 37 | 0.070 |
Why?
| | Communication | 1 | 2015 | 967 | 0.070 |
Why?
| | Autistic Disorder | 1 | 2011 | 211 | 0.070 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 372 | 0.070 |
Why?
| | Feasibility Studies | 1 | 2013 | 1095 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 2313 | 0.070 |
Why?
| | Massachusetts | 1 | 2008 | 180 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 348 | 0.070 |
Why?
| | Neuralgia, Postherpetic | 1 | 2008 | 40 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2011 | 312 | 0.070 |
Why?
| | Confidence Intervals | 2 | 2021 | 333 | 0.060 |
Why?
| | Observational Studies as Topic | 2 | 2018 | 129 | 0.060 |
Why?
| | Postal Service | 2 | 2008 | 27 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1990 | 0.060 |
Why?
| | Risk-Taking | 1 | 2009 | 328 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2026 | 115 | 0.060 |
Why?
| | Carbamazepine | 1 | 2025 | 22 | 0.060 |
Why?
| | Metoprolol | 1 | 2025 | 26 | 0.060 |
Why?
| | Mortality | 2 | 2019 | 376 | 0.060 |
Why?
| | Valproic Acid | 1 | 2025 | 48 | 0.060 |
Why?
| | Health Surveys | 3 | 2017 | 518 | 0.060 |
Why?
| | Sulfonylurea Compounds | 1 | 2025 | 51 | 0.060 |
Why?
| | Triazines | 1 | 2025 | 49 | 0.060 |
Why?
| | Insulin, Long-Acting | 1 | 2025 | 65 | 0.060 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2025 | 46 | 0.060 |
Why?
| | Cause of Death | 2 | 2019 | 472 | 0.060 |
Why?
| | Urban Health | 1 | 2005 | 96 | 0.050 |
Why?
| | Fructose | 1 | 2025 | 130 | 0.050 |
Why?
| | Rural Health | 1 | 2005 | 87 | 0.050 |
Why?
| | Parenting | 1 | 2008 | 318 | 0.050 |
Why?
| | Duloxetine Hydrochloride | 1 | 2024 | 10 | 0.050 |
Why?
| | Citalopram | 1 | 2024 | 32 | 0.050 |
Why?
| | Probability | 1 | 2005 | 312 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2025 | 126 | 0.050 |
Why?
| | Live Birth | 1 | 2024 | 68 | 0.050 |
Why?
| | Office Automation | 1 | 2004 | 5 | 0.050 |
Why?
| | Bupropion | 1 | 2024 | 47 | 0.050 |
Why?
| | Public Health Practice | 1 | 2004 | 63 | 0.050 |
Why?
| | Herpesvirus 3, Human | 2 | 2023 | 336 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2025 | 177 | 0.050 |
Why?
| | Patient Selection | 1 | 2007 | 719 | 0.050 |
Why?
| | Toxoids | 1 | 2023 | 1 | 0.050 |
Why?
| | Epidural Space | 1 | 2003 | 17 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2024 | 104 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3154 | 0.050 |
Why?
| | Spinal Cord Compression | 1 | 2003 | 22 | 0.050 |
Why?
| | Calcium Channel Blockers | 1 | 2024 | 165 | 0.050 |
Why?
| | Vibrio cholerae O1 | 1 | 2022 | 1 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 118 | 0.050 |
Why?
| | Drug Utilization | 2 | 2013 | 167 | 0.050 |
Why?
| | Travel-Related Illness | 1 | 2022 | 5 | 0.050 |
Why?
| | Antacids | 1 | 2022 | 16 | 0.050 |
Why?
| | Blood Group Antigens | 1 | 2022 | 15 | 0.050 |
Why?
| | Poverty Areas | 1 | 2002 | 42 | 0.050 |
Why?
| | Dehydration | 1 | 2022 | 56 | 0.050 |
Why?
| | Measles Vaccine | 1 | 2022 | 19 | 0.050 |
Why?
| | Metformin | 1 | 2025 | 319 | 0.040 |
Why?
| | Information Systems | 1 | 2021 | 57 | 0.040 |
Why?
| | Family Characteristics | 1 | 2023 | 197 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 427 | 0.040 |
Why?
| | Telephone | 1 | 2002 | 175 | 0.040 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2021 | 2 | 0.040 |
Why?
| | Algorithms | 2 | 2020 | 1839 | 0.040 |
Why?
| | Office Visits | 2 | 2015 | 90 | 0.040 |
Why?
| | Drug Labeling | 1 | 2021 | 37 | 0.040 |
Why?
| | Medication Adherence | 1 | 2025 | 539 | 0.040 |
Why?
| | Medicaid | 1 | 2025 | 462 | 0.040 |
Why?
| | Epidemiologic Research Design | 2 | 2013 | 29 | 0.040 |
Why?
| | Deltoid Muscle | 1 | 2020 | 6 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1099 | 0.040 |
Why?
| | Treatment Outcome | 4 | 2019 | 11695 | 0.040 |
Why?
| | Fever | 1 | 2022 | 312 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 26 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2020 | 141 | 0.040 |
Why?
| | Child Health Services | 1 | 2022 | 185 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 89 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 323 | 0.040 |
Why?
| | Graphic Novels as Topic | 1 | 2019 | 1 | 0.040 |
Why?
| | Student Health Services | 1 | 2019 | 15 | 0.040 |
Why?
| | Water | 1 | 2022 | 469 | 0.040 |
Why?
| | Orthomyxoviridae | 1 | 2019 | 40 | 0.040 |
Why?
| | Florida | 1 | 2019 | 117 | 0.040 |
Why?
| | Evidence-Based Practice | 1 | 2021 | 238 | 0.040 |
Why?
| | Medical Informatics | 1 | 2019 | 97 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 219 | 0.040 |
Why?
| | Pancreatitis | 1 | 2019 | 145 | 0.040 |
Why?
| | Birth Weight | 1 | 2021 | 522 | 0.030 |
Why?
| | Patient Safety | 1 | 2022 | 349 | 0.030 |
Why?
| | Gestational Age | 1 | 2021 | 975 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2024 | 916 | 0.030 |
Why?
| | Croup | 1 | 2018 | 19 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2018 | 155 | 0.030 |
Why?
| | Appendicitis | 1 | 2019 | 148 | 0.030 |
Why?
| | Minority Groups | 1 | 2019 | 282 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 854 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 783 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2017 | 105 | 0.030 |
Why?
| | Universities | 1 | 2019 | 452 | 0.030 |
Why?
| | Prediabetic State | 1 | 2019 | 245 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 268 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 367 | 0.030 |
Why?
| | Government Programs | 1 | 2015 | 26 | 0.030 |
Why?
| | Otitis Media | 1 | 2018 | 181 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1721 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2118 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2014 | 200 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2015 | 239 | 0.020 |
Why?
| | Off-Label Use | 1 | 2013 | 51 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1958 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2013 | 182 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 358 | 0.020 |
Why?
| | Quality Control | 1 | 2012 | 163 | 0.020 |
Why?
| | Tetanus Toxoid | 1 | 2012 | 34 | 0.020 |
Why?
| | Triglycerides | 1 | 2014 | 521 | 0.020 |
Why?
| | Encephalitis | 1 | 2014 | 142 | 0.020 |
Why?
| | Professional Practice Location | 1 | 2011 | 26 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4293 | 0.020 |
Why?
| | Bell Palsy | 1 | 2011 | 9 | 0.020 |
Why?
| | Physical Examination | 1 | 2013 | 240 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2012 | 129 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2010 | 13 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 2092 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1660 | 0.020 |
Why?
| | Pharmaceutical Services | 1 | 2011 | 78 | 0.020 |
Why?
| | Income | 1 | 2012 | 202 | 0.020 |
Why?
| | Schools | 1 | 2014 | 453 | 0.020 |
Why?
| | Fees, Pharmaceutical | 1 | 2010 | 8 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2011 | 240 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2011 | 465 | 0.020 |
Why?
| | Health Behavior | 1 | 2013 | 786 | 0.020 |
Why?
| | Health Care Rationing | 1 | 2007 | 60 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2008 | 140 | 0.020 |
Why?
| | Demography | 1 | 2008 | 288 | 0.020 |
Why?
| | Intussusception | 1 | 2007 | 25 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2011 | 901 | 0.020 |
Why?
| | Mass Media | 1 | 2005 | 41 | 0.010 |
Why?
| | Perception | 1 | 2007 | 377 | 0.010 |
Why?
| | Policy Making | 1 | 2004 | 82 | 0.010 |
Why?
|
|
Daley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|